̽»¨¾«Ñ¡

A global panel for the characterization of small molecules commonly present in biological matrices. Compounds are characterized using their chromatographic retention times and one selected reaction monitoring (SRM) transition. For most compounds, a second SRM is used for additional confirmation. Typical families of compounds screened include:

• Amino acids and derivatives
• TCA metabolites
• Nucleotides and nucleosides
• Carbohydrates
• Organic acids
• Vitamins and their metabolites
• Bile acids
• Carnitines

Check the list of metabolites (link a Google Docs).

If not present, your metabolite of interest can, if technically feasible, be included on demand in the panel.

A global panel for the characterization of lipid species from the most common families commonly present in biological matrices. Compounds are characterized using their chromatographic retention times and, at least, one class-specific selected reaction monitoring (SRM) transition. Lipids screened belong to the following classes:

• Sphingolipids
• Phosphatidylcholines
• Phosphatidylethanolamines
• Phosphatidylserines
• Diacylglycerols
• Triacylglycerols
• Fatty acids

Check the list of currently screened lipids (link a Google Docs).

If not present, your lipid of interest can, if technically feasible, be included on demand in the panel.

A global panel for the quantification of oxylipins derived from different polyunsaturated fatty acids. We have experience commonly present in biological matrices. Compounds are characterized using their chromatographic retention times and, at least, one class-specific selected reaction monitoring (SRM) transition.

Different panels exist, depending on the oxylipins and matrix of interest.

• General oxylipin platform
• Urinary eicosanoid platform
• Octadecanoid metabolism platform

Custom designed experiments to follow the metabolic reactions of your compounds.

Includes method development and sample analyses for the detection and quantitation of drugs and/or their metabolites from biological samples of different sources. This can be used in pharmacokinetics, drug metabolism, biotransformation, and bioaccumulation analyses. 

For full quantification, we use standard calibration curves and internal standards selected for the study. Our lab is currently non-GMP, but method validation can be performed following the FDA and EMA guidelines.

Includes method development and sample analyses for the detection and quantitation of other metabolites not covered in the broad screening panels. The lack of coverage could be due to many reasons. We can use our expertise to offer different strategies to overcome them. For instance:

• Lack of sensitivity. For low abundant metabolites, we can improve their detection by using special sample treatment protocols using our automated extraction system from Extrahera and analyzing the samples in the most sensitive triple-quadrupole from the core.
• Lack of specificity. Small molecules can be present in several isomeric species such as cis-trans or R/S. If necessary, we can use further develop our separation strategies (based on UPLC and SFC) to ensure that the measured form is the one of interest. 

For full quantification, we use standard calibration curves and internal standards selected for the study. Our lab is currently non-GMP, but method validation can be performed following the FDA and EMA guidelines.